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Summary
Objective: The role of oxidative stress in disease progression has been shown to be more
complicated in HIV-infected individuals receiving highly active antiretroviral therapy (HAART)
compared to those who remain treatment-naı¨ve. This study examined the changes in the
antioxidant profile of HIV-infected subjects who remained HAART-naı¨ve due to a high CD4 cell
count and HIV-negative controls, over a 12-month follow-up period at YRG CARE, a tertiary HIV
referral centre in southern India.
Methods: We prospectively studied 35 HIV-infected participants (18 on d4T+3TC+EFV (stavudi-
ne + lamivudine + efavirenz), eight on AZT+3TC+EFV (zidovudine + lamivudine + efavirenz), and
nine who were antiretroviral therapy-naı¨ve) and 20 HIV-negative controls. Antioxidant profile
(total antioxidant status, glutathione reductase, glutathione peroxidase, uric acid, ceruloplas-
min, zinc, and albumin), CD4 cell count, plasma viral load, dietary intake, and history of smoking
and alcohol use were determined at baseline and at twelve months.
Results: At 12 months, participants on HAART showed a significant increase in glutathione
peroxidase (baseline: 1765 vs. 12 months: 2850 U/l; p < 0.001) and albumin (3.6 vs. 4.4 g/dl;
p < 0.001), and a significant decrease in glutathione reductase (52.6 vs. 50.5 U/l; p = 0.054) and
uric acid (5.4 vs. 4.8 mg/dl; p = 0.027) compared to baseline. Also HAART-naı¨ve participants had a
significant increase in albumin (baseline: 3.7 vs.12 months: 4.3 g/dl; p = 0.023) and a significant
decrease in zinc levels (baseline: 79.0 vs.12 months: 74.5 mg/dl; p = 0.052) from baseline to 12
months. HIV-negative subjects had a significant increase in glutathione reductase at 12 months
from baseline (baseline: 37 vs.12 months: 39 U/l; p = 0.002). No significant difference in total* Corresponding author. Tel.: +91 44 22542929; fax: +91 44 22542939.
E-mail address: kumarasamy@yrgcare.org (N. Kumarasamy).
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antioxidant status, ceruloplasmin, and zinc levels were observed in HAART-experienced subjects and
negative controls over the 12-month follow-up period.
Conclusion: This study documents changes in antioxidants over a period of time in HAART-experi-
enced subjects in a southern India setting.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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HIV disease results in considerable morbidity and mortality
due to opportunistic infections (OIs) that can be effectively
managed with the prompt initiation of highly active antire-
troviral therapy (HAART) in HIV-infected individuals.1 How-
ever, recent studies have documented the possibility of
increasing toxicities and metabolic changes with the long-
term use of HAART.2—4 Cells contain several enzymatic and
non-enzymatic antioxidants to prevent or limit reactive
oxygen species (ROS)-associated damage.5 The defense sys-
tem involves many compounds with vastly different proper-
ties: enzymes (superoxide dismutase, catalase, glutathione
peroxidase), macromolecules (albumin, ceruloplasmin), and
small molecules (vitamin C, vitamin E, b-carotene, reduced
glutathione, and uric acid).
ROS may enhance viral replication by activating nuclear
transcription factors such as nuclear factor-kB (NF-kB),
which might ultimately lead to an increased rate of viral
gene expression.6 In the pre-HAARTera, several studies found
that both asymptomatic and symptomatic HIV-infected indi-
viduals are at increased risk of oxidative stress, including
raised plasma metabolites of lipid peroxidation (LPO) and
reduced antioxidant levels, compared with non-HIV-infected
control participants.7,8 Certain micronutrients may play a
key role in maintaining normal immune functions that may
protect immune effector cells from oxidative damage.9
As the natural history and disease progression of HIV can
vary across ethnic and racial groups, it is necessary to identify
the exact role of oxidative stress and changes in the anti-
oxidant profile among the HIV-infected on HAART in southern
India. The present study was undertaken to examine the
changes in antioxidant profile among HIV-infected partici-
pants on generic HAART, participants who remained HAART-
naı¨ve, and HIV-negative controls.
Patients and methods
Setting and subjects
This prospective study was conducted at YR Gaitonde Centre
for AIDS Research and Education (YRG CARE), a non-profit HIV
referral centre in southern India, providing medical and
psychosocial care to over 10 000 individualswithHIV infection.
A total of 35 HIV-infected subjects (26 on HAART, nine HAART-
naı¨ve) and 20 HIV-negative controls were included in the
study. All the participants were involved in other clinic-based
research studies. Study participants from prior studies were
selected due to limitations in funding. All the laboratory
investigationswere done at baseline and at 12months. Dietary
datawere collected using a 24-h recall, and the nutritive value
was calculated using indigenous software ‘DIGEST’.HIV-infected participants met the following inclusion
criteria: >18 years of age, HIV-positive, antiretroviral
therapy (ART)-naı¨ve prior to initiating HAART, and without
any active OIs. HIV-infected participants who remained
naı¨ve did not require HAART due to their high CD4 count.
HIV-positive participants were either teetotalers or had
quit smoking and drinking on knowing their HIV status.
All HIV-infected participants were on vitamin and mineral
supplementation.
HIV-negative control participants had no serological evi-
dence of HIV and/or HCV-infection, were not smokers or
drinkers, had no abnormal laboratory findings (complete
blood count, AST and ALT levels within normal range), and
had normal blood pressure (120/80 mmHg), a body mass
index (BMI) in the range 18.6—25.2 kg/m2, normal chest X-
ray, and normal electrocardiogram.
The YRG CARE institutional review board approved the
study protocol. Written informed consent was obtained from
all the individuals enrolled in the study.
Specimens
To analyze serum albumin, uric acid, total antioxidant status
(TAS), ceruloplasmin, and glutathione reductase (GR), 5 ml of
peripheral blood was drawn after an overnight fast. Addi-
tionally, 3.5 ml of blood was collected into EDTA-containing
tubes (BDVacutainer1, BD, Franklin Lakes, NJ, USA) to deter-
mine glutathione peroxidase (GPx). Two aliquots of serum
and plasma were stored at 80 8C, protected from light, and
thawed only once.
Immunological and virological markers
Plasma viral load (PVL) was determined by the Cobas Ampli-
cor HIV-1 Monitor Assay version 1.5 (Roche Molecular Sys-
tems, Branchburg, NJ, USA); results below the limit of
detection were assigned a value of<400 copies/ml. Absolute
CD4 T-lymphocyte counts were determined using the Guava
Personal Cell Analyzer (Guava Technologies, Inc., USA).
Estimation of antioxidant levels
TAS, GR, GPx, and ceruloplasmin levels were measured using
commercial kits procured from Randox Laboratories, UK, and
Aptec Diagnostics, Belgium.
The TAS test measures the total antioxidant effect; ABTS
(2,20-azinobis(3-ethylbenzothiazoline-6-sulfonate)) reacts
with all of the defense systems in the circulation, namely
superoxide dismutase (SOD), GPx and metal-binding protein
(e.g., ceruloplasmin), uric acid, albumin, and DNA repair
enzymes. For TAS quantitation, Randox kit Cat. No. NX2332
(Randox Laboratories Ltd, Crumlin, UK) was used.
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kit Cat. No. RS504 (Randox Laboratories Ltd). GPx reduces
H2O2 to H2O by oxidizing glutathione (GSH). Re-reduction of
the oxidized form of glutathione (GSSG) is then catalyzed by
glutathione reductase. The decrease in absorbance at 340 nm
was measured.10
The activity of GR was determined by using Randox diag-
nostic reagents (GR 2368; Randox Laboratories Ltd).
The level of ceruloplasmin was determined by immunotur-
bidometric method using an Olympus AU 400 autoanalyzer
(Olympus Optical, Japan). It has been shown that ceruloplas-
min, a copper-dependent acutephaseprotein, has antioxidant
functions that can prove beneficial in several pathological
conditions.
The level of uric acid was determined using Raichem
diagnostic reagents (Hemagen Diagnostics Inc., San Diego,
CA, USA) by uricase method.
It has been shown that albumin levels <3.0 g/dl are
associated with decreased survival in HIV-infected indivi-
duals. Serum albumin was estimated using Olympus diagnos-
tic reagents (Olympus Diagnostica, GmbH, Ireland) by
bromocresol green (BCG) method.
Low levels of plasma zinc predict a three-fold increase in
HIV-related mortality. Zinc acts as an antioxidant or helps
such functions, which not only regulate the immune
responses of the host, but may also alter the genome of
the viruses. Zinc was estimated using Chema diagnostic
reagents (Chema Diagnostica, Italy) by photometric method.
Statistical analysis
Descriptive statistics, Chi-square statistics, and the Mann—
Whitney U-test were used. Statistical analyses were per-
formed with Statistical Package for Social Sciences softwareTable 1 Demographic and laboratory characteristics of study pa
Characteristics HAART-experienced (N = 26)
Mean age (SD) in years 32.3 (7.1)
Sex
Male 17 (65.4)
Female 9 (34.6)
Median BMI kg/m2 (IQR) 16.86 (15.3—19.7)
Median CD4 cells/ml (IQR)
Baseline 167 (116—219)
12 months 338 (281—429)
Median PVL copies/ml (IQR)
Baseline 286 500 (117 500—696 710)
12 months <400
Energy (kcal)
Baseline 2879 (845)
12 months 2605 (619)
Protein (g)
Baseline 94.1 (41.1)
12 months 80.9 (22.8)
HAART, highly active antiretroviral therapy; SD, standard deviation; BMI
NA, not applicable.(SPSS, version 13.0, Chicago, IL, USA). A p value of less than
0.05 was considered statistically significant.
Results
Among the 35 HIV-infected subjects investigated, 26 were
treated with HAART and nine were HAART-naı¨ve; there were
20 HIV-negative controls. The mean age in the HAART-experi-
enced, HAART-naı¨ve, and the control groups was 32  7.1,
29  6.3, and 29  6.0 years, respectively. Over two-thirds
(65%) of HAART-experienced participants, 44% of HAART-
naı¨ve participants, and 50% of controls were male. The
baseline characteristics of the study population are shown
in Table 1.
At baseline, the median BMI was 16.9, 19.9, and 21.2 kg/
m2 in the HAART-experienced, HAART-naı¨ve, and the control
groups, respectively. HAART-experienced participants had a
median CD4 count of 167 cells/ml (interquartile range (IQR)
116—219) and a higher viral load of 286 500 copies/ml (IQR
117 500—696 710) compared to HAART-naı¨ve participants
who had a median CD4 of 418 cells/ml (IQR 293—624) and
viral load of 22 400 copies/ml (400—193 000). Also at base-
line, HAART-experienced participants had a higher mean
calorie intake of 2879 kcal and a protein intake of 94.1 g
than the HAART-naı¨ve participants whose calorie intake was
2320 kcal and protein intake 75.1 g. Among the HAART-
experienced group, 69% of participants received
d4T+3TC+EFV (stavudine + lamivudine + efavirenz) and 31%
received AZT+3TC+EFV (zidovudine + lamivudine + efavir-
enz).
The antioxidant profiles of all three groups are shown in
Table 2. At baseline, albumin (3.6 vs. 3.7 vs. 4.8 g/dl) and
zinc (71.0 vs. 79.0 vs. 92.5 mg/dl) were significantly lower
and GR (52.6 vs. 46.0 vs. 37.0 U/l), uric acid (5.4 vs. 4.8 vs.rticipants
HAART-naı¨ve (N = 9) Control (N = 20)
29.4 (6.35) 29 (6.0)
4 (44.4) 10 (50)
5 (55.6) 10 (50)
19.95 (16.23—26.4) 21.2 (18.6—25.2)
418 (293—624) NA
416 (246—668)
22 400 (400—193 000) NA
22 900 (400—115 000)
2320 (864) Not collected
2397 (498)
75.1 (33.8) Not collected
73.0 (28.3)
, body mass index; IQR, interquartile range; PVL, plasma viral load;
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e64 M. Sundaram et al.4.1 mg/dl), and ceruloplasmin (31 vs. 25 vs. 26 mg/dl)
were significantly higher among the HIV-infected participants
who were at a more advanced stage of HIV disease and about
to initiate HAART as compared to the HIV-infected partici-
pants who would remain ART-naı¨ve and the HIV-negative
controls.
Participants in the three groups did not experience sig-
nificant changes in TAS from baseline to 12 months. From
baseline to 12 months, GPx significantly increased (1765 U/l
to 2850 U/l) in the HAART-experienced group ( p  0.001).
Additionally from baseline to 12 months, HAART-experienced
participants underwent a significant decrease in their uric
acid levels (5.4 mg/dl to 4.8 mg/dl; p = 0.027).
From baseline to 12 months, HAART-experienced parti-
cipants experienced a significant increase in their median
albumin levels (3.6 g/dl to 4.4 g/dl; p < 0.001). Similarly
HAART-naı¨ve participants experienced a significant
increase in their median albumin levels (3.7 g/dl to
4.3 g/dl; p = 0.002) and significant decrease in their med-
ian zinc levels from baseline to 12 months (baseline: 79.0
vs. 12 months: 74.5 mg/dl; p = 0.052). At 12 months, GR
significantly increased in the control group (37 U/l to 39 U/
l; p = 0.002) and significantly decreased in the HAART-
experienced group from baseline (52.6 U/l to 50.5 U/l;
p = 0.054). HAART-experienced participants and HIV-nega-
tive controls did not experience significant changes in their
median zinc and ceruloplasmin levels from baseline to 12
months. There was also no significant difference in the
dietary intake of the HIV-infected subjects from baseline
to 12 months.
Discussion
This study documents alterations in the levels of GPx,
albumin, GR, and uric acid between baseline and 12
months among HAART-experienced participants. Studies
from the developed world have documented biochemical
changes that could be a result of greater utilization of
antioxidant micronutrients subsequent to increased oxida-
tive stress rather than inadequate dietary intake11 or
malabsorption,12 inadequate nutrient release from the
liver, acute infections, and/or inadequate availability of
carrier molecules that may influence circulating antioxi-
dant concentrations.13—15
This study suggests that enhanced oxidative stress and
disturbed glutathione metabolism occur after initiating
HAART. These effects appear to be related to persistent
tumor necrosis factor-a (TNF-a) activation in HIV-infected
patients. HIV-infected individuals have been shown to have
decreased antioxidant concentrations, disruption in glu-
tathione metabolism, and enhanced spontaneous generation
of ROS.16 Furthermore, a significant decrease in GR levels was
documented in treated patients at 12 months. To be cogni-
zant, lower GR levels and oxidative stress in general are
known to upregulate inflammatory cytokine activities in
patients receiving HAART. HIV-infected individuals can have
significantly higher GPx activity than HIV-uninfected indivi-
duals.17 We found that HIV-infected individuals receiving
HAART experienced increased levels of GPx over time. GPx
plays an important role in themetabolism of ROS as a defense
mechanism against oxidative damage by catalyzing the
reduction of a variety of hydroperoxides via glutathione as
Changes in antioxidant profile and HAART, India e65the reducing substrate. In addition to its role as a substrate in
the GSH redox cycle, glutathione also acts as a direct endo-
genous scavenger of hydroxyl radicals, and is involved in the
detoxification and metabolism of a number of chemicals and
drugs in the liver. The changes observed in the current study
therefore reveal that antioxidant supplementation, including
glutathione, might have an effect on oxidative stress in HIV-
infected individuals. Antioxidant enzyme levels are sensitive
to oxidative stress; alterations were observed in the present
study, which prove the cell damage and weakened antiox-
idant defense in HIV-infected individuals.
The current study found that HIV infection can increase
the oxidative stress process, which is then further increased
by HAART usage; this finding is in line with other studies.18
In HIV infection, ROS species may enhance viral replica-
tion by activating nuclear transcription factors, which ulti-
mately could lead to viral gene expression.19 The deficiency
of total antioxidant status might markedly increase oxidative
stress, possibly adversely affecting the immune response and
predisposing to drug toxicity.20
The current study found significant changes in antiox-
idants such as GR, GPx, uric acid, and albumin among
HAART-experienced participants over a period of time.
Supplementation with glutathione or antioxidants may
improve immunological and virological indices in HIV-
infected individuals.16 These agents may positively act on
the individuals’ immunological status and decrease HIV
replication. Further, a greater understanding of the forma-
tion of ROS and the subsequent oxidative stress is important
for effective clinical care of HIV-infected individuals. Clin-
ical guidelines that indicate cellular damage due to oxida-
tive stress need to be established and monitored during
HAART treatment. Current drug therapies and other ther-
apeutic measures such as administration of N-acetylcys-
teine supplements, may improve the quality of patient
care, in addition to diet counseling.
This study demonstrates that changes in antioxidants
are observed among HAART-experienced participants in the
southern India setting. Further long-term prospective
studies on a large population must be designed to sub-
stantiate and evaluate the relationship between antiox-
idants and disease progression in persons receiving HAART
among HIV-infected individuals, especially in resource-
limited settings.
This study had certain limitations viz. limited funding,
small sample size, and inadequacy of follow-up (for 12
months). Furthermore, there were certain constraints with
regard to including more parameters related to oxidative
stress, largely due to lack of funds. The analytical stability
of the kits and pre-analytical variables were also a chal-
lenge. In addition, the study was probably underpowered
to detect some of the parameter changes over a period of
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